Hormone replacement therapy: Current controversies

Minerva Ginecologica

Volumn 55, Issue 2, 2003, Pages 107-116

  Burkman, R T ^a,b  

^a BAYSTATE MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast neoplasms; Cardiovascular diseases; Colonic neoplasms; Hormone replacement therapy; Osteoporosis

Indexed keywords

ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; PROGESTERONE;

ADULT; AGED; BREAST CANCER; CANCER RISK; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE ASSOCIATION; DRUG EFFECT; DRUG INDICATION; DRUG USE; FEMALE; FRAGILITY FRACTURE; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; OSTEOPENIA; OSTEOPOROSIS; REVIEW; RISK FACTOR; STROKE; THROMBOEMBOLISM; TREATMENT INDICATION; VEIN THROMBOSIS;

BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; COLONIC NEOPLASMS; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; OSTEOPOROSIS; PROGESTERONE;

EID: 0038339562     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. American College of Obstetricians and Gynecologists. Hormone replacement therapy. ACOG Tech Bull 1992;166.
2. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:304-13.
3. Bush TL Whiteman M, Flaws JA. Hormone replacement therapy and breast cancer: a qualitative review. Obstet Gynecol 2001;98:498-508.
4. The Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996;276:1389-96.
5. Kiel DP, Felson DT, Anderson JJ, Wilson PW, Moskowitz MA. Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study. N Engl J Med 1987;317:1169-74.
6. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991;325:756-62.
7. Wagner JD. Rationale for hormone replacement therapy in atherosclerosis prevention. J Reprod Med 2000;45:245-58.
8. Hu FB, Stampfer MJ, Manson JE, Grodstein F, Colditz GA, Speizer FE et al. Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women. N Engl J Med 2000;343:530-7.
9. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
10. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-9.
11. The Writing Group for the Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
12. Crandall CJ. Estrogen replacement therapy and colon cancer: a clinical review. J Womens Health Gend Based Med 1999;8:1155-66.
13. Nanda K, Bastian LA, Hasselblad V, Simel DL. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol 1999;93:880-8.
14. About women, heart disease, and stroke. American Heart Association, 2000.
15. The Writing Group for the PEP Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmeno-pausal estrogen/progestin interventions (PEPI) trial. JAMA 1995;273:199-208.
16. Sack MN, Rader DJ, Cannon RO 3rd. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 1994;343:269-70.
17. LaRosa JC. Metabolic effects of estrogens and progestins. Fertil Steril 1994;62:140S-6.
18. Adams MR, Kaplan JR, Manuck SB, Koritnik DR, Parks JS, Wolfe MS et al. Inhibition of coronary artery atherosclerosis by 17-β estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arterio-sclerosis 1990;10:1051-7.
19. Reis SE, Gloth ST, Blumenthal RS, Resar JR, Zoxur HA, Gerstenblith G et al. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation 1994;89:52-60.
20. Holm P, Andersen HL, Andersen MR, Erhardtsen E, Stender S. The direct antiatherogenic effect of estrogen is present, absent, or reversed, depending on the state of the arterial endothelium. A time course study in cholesterol-clamped rabbits. Circulation 1999;100:1727-33.
21. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57.
22. Shlipak MG, Simon JA, Vittinghoff E, Lin F, Barrett-Connor E, Knopp RH et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 2000;283:1845-52.
23. Clarke S, Kelleher J, Lloyd-Jones H, Sharples L, Slack M, Schofield PM. Transdermal hormone replacement therapy for secondary prevention of coronary artery disease in postmenopausal women. Eur Heart J 2000;21 Suppl:212.
24. Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ 1997;315:149-53.
25. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996;348:981-3.
26. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996;348:977-80.
27. Hulley S, Furberg C, Barrett-Connor E, Conley J, Grady D, Haskell W et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:58-66.
28. Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996;348:983-7.
29. Paganini-Hill A, Ross RK, Henderson BE. Postmenopausal oestrogen treatment and stroke: a prospective study. BMJ 1988;297:519-22.
30. Falkeborn M, Persson I, Terent A, Adami HO, Lithell H, Bergstrom R. Hormone replacement therapy and the risk of stroke: follow-up of a population based cohort in Sweden. Arch Intern Med 1993;153:1201-9.
31. Finucane FF, Madans JH, Bush TL, Wolf PH, Kleinman JC. Decreased risk of stroke among postmenopausal hormone users. Results from a national cohort. Arch Intern Med 1993;153:73-9.
32. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59.
33. Ries LAG, Eisner MP, Kosary CL. SEER Cancer Statistics Review, 1973-1998. Bethesda: National Cancer Institute, 2001.
34. Persson I, Weiderpass E, Bergkvist L, Bergstrom R, Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 1999;10:253-60.
35. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 1999;81:339-44.
36. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol 1993;168:1473-9.
37. Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol 2000;152:950-64.
38. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-91.
39. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328-32.
40. Chen CL, Weiss NS, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancer. JAMA 2002;287:734-41.
41. Newcomer LM, Newcomb P, Daling JR, Yasui Y, Potter JD. Postmenopausal hormone use and risk of breast cancer by histologic type. Society of Epidemiologic Research Annual Meeting, Baltimore, MD, USA, June-10-12, 1999.
42. Li CI, Weiss NS, Stanford JL, Daling JR. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer 2000;88:2570-7.
43. Nanda K, Bastian LA, Schulz K. Hormone replacement therapy and the risk of death from breast cancer: a systematic review. Am J Obstet Gynecol 2002;186:325-34.
44. Raafat AM, Hofseth LJ, Haslam SZ. Proliferative effects of combination estrogen and progesterone replacement therapy on the normal postmenopausal mammary gland in a murine model. Am J Obstet Gynecol 2001;184:340-9.
45. Raafat AM, Li S, Bennett JM, Hofseth LJ, Haslam SZ. Estrogen and estrogen plus progestin act directly on the mammary gland to increase proliferation in a postmenopausal mouse model. J Cell Physiol 2001;187:81-9.
46. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999;84:4559-65.
47. Greendale GA, Reboussin BA, Sie A, Singh HR, Olson LK, Gatewood O et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med 1999;130:262-9.
48. Lundstrom E, Wilczek B, von Palffy Z, Soderqvist G, von Schoultz B. Mammographic breast density during hormone replacement therapy: differences according to treatment. Am J Obstet Gynecol 1999;181:348-52.
49. Foidart JM, Colin C, Denoo X, Desreux J, Beliard A, Fournier S et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 1998;69:963-9.
50. MacLennan SC, MacLennan AH, Ryan P. Colorectal cancer and oestrogen replacement therapy. A meta-analysis of epidemiological studies. Med J Aust 1995;162:491-3.
51. Hebert-Croteau N. A meta-analysis of hormone replacement therapy and colon cancer in women. Cancer Epidemiol Biomarkers Prev 1998;7:653-9.
52. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 1999;106:574-82.
53. Persson I. Cancer risk in women receiving estrogen-progestin replacement therapy. Maturitas 1996;23 Suppl:S37-45.
54. Newcomb PA, Storer BE. Postmenopausal hormone use and risk of large-bowel cancer. J Natl Cancer Inst 1995;87:1067-71.
55. Troisi R, Schairer C, Chow WH, Schatzkin A, Brinton LA, Fraumeni JF jr. A prospective study of menopausal hormones and risk of colorectal cancer (United States). Cancer Causes Control 1997;8:130-8.
56. Grodstein F, Martinez ME, Platz EA, Giovannucci E, Colditz GA, Kautzky M et al. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med 1998;128:705-12.
57. Jacobson JS, Neugut AI, Garbowski GC, Ahsan H, Waye JD, Treat MR et al. Reproductive risk factors for colorectal adenomatous polyps (New York City, NY, United States). Cancer Causes Control 1995;6:513-8.
58. Peipins LA, Newman B, Sandler RS. Reproductive history, use of exogenous hormones, and risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 1997;6:671-5.
59. Potter JD, Bostick RM, Grandits GA, Fosdick L, Elmer P, Wood J et al. Hormone replacement therapy is associated with lower risk of adenomatous polyps of the large bowel: the Minnesota Cancer Prevention Research Unit Case-Control Study. Cancer Epidemiol Biomarkers Prev 1996;5:779-84.
60. McMichael AJ, Potter JD. Reproduction, endogenous and exogenous sex hormones, and colon cancer: a review and hypothesis. J Natl Cancer Inst 1980;65:1201-7.
61. Everson GT, McKinley C, Kern F jr. Mechanisms of gallstone formation in women. Effects of exogenous estrogen (Premarin) and dietary cholesterol on hepatic lipid metabolism. J Clin Invest 1991;87:237-46.
62. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB, Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 1994;7:536-40.
63. Singh S, Paraskeva C, Gallimore PH, Sheppard MC, Langman MJ. Differential growth response to oestrogen of premalignant and malignant colonic cell lines. Anticancer Res 1994;14:1037-41.
64. Lointier P, Wildrick DM, Boman BM. The effects of steroid hormones on a human colon cancer cell line in vitro. Anticancer Res 1992;12:1327-30.
65. Campagnoli C, Biglia N, Altare F, Lanza MG, Lesca L, Cantamessa C et al. Differential effects of oral conjugated estrogens and transdermal estradiol on insulin-like growth factor 1, growth hormone and sex hormone binding globulin serum levels. Gynecol Endocrinol 1993;7:251-81.
66. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
67. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001;285:2891-7.
68. Eastell R. Treatment of postmenopausal osteoporosis. N EngI J Med 1998;338:736-46.
69. Nelson HD. Assessing benefits and harms of hormone replacement therapy: clinical applications. JAMA 2002;288:882-4.